Trust Signals
Written by: FormBlends Medical Team. Reviewed: 2026-05-29. Standard: Claims graded by evidence type; no financial relationship with any compounding pharmacy listed. Sources are peer-reviewed or FDA documents only. Speculative claims are labeled as such.Key Takeaways
- Rapamycin is an FDA-approved prescription drug (sirolimus), not a legal OTC supplement. Any product marketed as a "rapamycin supplement" without a prescription is either a different compound or non-compliant.
- In the NIA Interventions Testing Program, rapamycin extended median lifespan in genetically heterogeneous mice by roughly 9% in males and 14% in females when started at 20 months of age. This is among the most replicated longevity findings in rodent biology.
- Human evidence is limited to small mechanistic studies and the PEARL trial (a phase 2 RCT in postmenopausal women), which showed biomarker changes but no lifespan data.
- Bioavailability of oral sirolimus averages roughly 15% (tablets) to higher for solutions; a high-fat meal raises peak exposure by approximately 34%. Formulation and diet timing are not minor variables.
- The nearest legal OTC alternatives (berberine, spermidine, fisetin) act through overlapping but mechanistically distinct and pharmacologically weaker pathways. They are not equivalents.
What Is the Best Rapamycin Supplement?
There is no legal best rapamycin supplement sold OTC, because rapamycin (sirolimus) is a Schedule-unscheduled but prescription-only FDA-approved drug. The most defensible path for adults pursuing mTOR inhibition is compounded sirolimus from an FDA-registered 503A or 503B pharmacy with a valid prescription, verified purity via third-party HPLC, and physician supervision. OTC products claiming to be rapamycin supplements are either mislabeled or contain different compounds.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What exactly is rapamycin and why do people want it?
- Is rapamycin legal to buy as a supplement?
- What does the evidence actually show? (Evidence Ledger)
- How does rapamycin work at the molecular level?
- What most rapamycin pages get wrong
- Bioavailability and formulation: why it matters more than people realize
- Honest head-to-head: rapamycin vs. real alternatives
- How to read a compounded rapamycin product and its COA
- Dosing protocols in the literature
- Drug and supplement interactions you cannot ignore
- FAQ
- Sources
What Exactly Is Rapamycin and Why Do People Want It?
Rapamycin (INN: sirolimus) is a macrolide compound originally isolated from Streptomyces hygroscopicus bacteria found in a soil sample from Easter Island (Rapa Nui, hence the name). It reached FDA approval in 1999 as an immunosuppressant for kidney transplant rejection prevention under the brand name Rapamune (Pfizer/Wyeth).
Interest in rapamycin as a longevity compound stems from its role as a selective inhibitor of the mechanistic target of rapamycin complex 1 (mTORC1), a kinase that sits at a central node integrating nutrient availability, growth factor signaling, and cellular energy status. Dysregulated mTOR activity is implicated in aging biology across species, making it a legitimate pharmacological target. The interest is scientifically grounded. The hype surrounding OTC "rapamycin supplements" is not.
Is Rapamycin Legal to Buy as a Supplement?
Products sold online as "rapamycin supplements" fall into several categories, none of which are pharmaceutical sirolimus sold legally OTC:
- Rapalog analogues: Compounds like everolimus that require their own prescriptions and have distinct pharmacokinetics.
- Putative natural mTOR inhibitors: Berberine, resveratrol, fisetin, spermidine. These have OTC legal status but are not rapamycin.
- Gray-market API products: Raw sirolimus API sold as "research use only." Quality is unverified and use is outside any regulatory framework.
- Mislabeled products: Products that list rapamycin or sirolimus on a label without containing meaningful quantities. These are FDA enforcement targets.
What Does the Evidence Actually Show?
| Claim | Best Evidence Type | Effect Direction | Confidence | Key Caveat |
|---|---|---|---|---|
| Extends lifespan in mice (late-start dosing) | Multi-site replicated animal RCT (NIA ITP) | Positive (roughly 9 to 14% median increase) | High (in mice) | Does not prove human lifespan extension |
| Improves immune function in elderly humans (flu vaccine response) | Human RCT (Mannick et al., 2014, n=218) | Positive (approximately 20% increase in vaccine response) | Moderate | Used RTB101, a rapalog, not pure sirolimus; single endpoint |
| Reduces p16 (senescence marker) in skin in postmenopausal women | Phase 2 RCT (PEARL trial, Mannick et al., 2021) | Positive trend at 1 mg/day | Low to Moderate | Small n, biomarker only, no clinical outcome |
| Extends lifespan in humans | None (mechanism and animal data only) | Unknown | Very Low | No human RCT with lifespan endpoint exists |
| Reduces mTORC1 activity (S6K1 phosphorylation) in humans at low doses | Human PK/PD studies | Positive, dose-dependent | High (mechanistic) | Biomarker effect does not prove longevity benefit |
| Mouth sores and lipid elevation as side effects at low doses | Human clinical trials and transplant literature | Adverse (dose-dependent incidence) | High | Rates at once-weekly low doses not fully quantified in healthy adults |
| OTC berberine meaningfully replicates rapamycin's mTOR effects | Cell/animal studies, indirect mechanisms | Partial overlap, much weaker | Very Low | No human comparison data; different mechanism (AMPK, not FKBP12) |
How Does Rapamycin Work at the Molecular Level?
Sirolimus enters cells and binds FKBP12 (FK506-binding protein 12). The sirolimus-FKBP12 complex then docks on the FKBT12-rapamycin-binding (FRB) domain of mTOR, allosterically inhibiting mTORC1 but largely sparing mTORC2 at standard doses.
The downstream consequences of mTORC1 inhibition relevant to aging biology include:
- S6K1 dephosphorylation: Reduces ribosomal protein synthesis and cell growth signals. S6K1 knockout mice live longer, providing indirect genetic validation of this pathway.
- 4E-BP1 dephosphorylation: Reduces cap-dependent mRNA translation, slowing production of growth-promoting proteins.
- ULK1 release: mTORC1 normally phosphorylates and suppresses ULK1 (an autophagy initiating kinase). Inhibiting mTORC1 allows ULK1 to activate autophagy, the cellular recycling process implicated in proteostasis and longevity.
What this mechanism does NOT prove: That pharmacological mTORC1 inhibition at any dose in healthy humans produces the same longevity effects as genetic models. The timing, duration, and tissue-specificity of mTOR modulation matter. Chronic mTORC1 inhibition can impair wound healing, insulin signaling via S6K1 feedback, and immune surveillance. The "intermittent dosing spares mTORC2" hypothesis is pharmacologically plausible but not proven in humans.
What Most Rapamycin Pages Get Wrong
Most pages on this topic commit at least one of four errors:
- They call compounded sirolimus a "supplement." It is a compounded drug. The distinction matters legally, for dosing precision, and for safety monitoring. Calling it a supplement implies the safety profile of a vitamin. It does not have one.
- They present mouse lifespan data as near-certain human evidence. Mice have a much shorter lifespan, very different mTOR biology relative to body mass, and the ITP protocol used a diet-incorporated dose that does not map cleanly to human oral dosing. The mouse data is compelling scientific rationale, not a clinical trial in humans.
- They ignore the bioavailability problem. Oral sirolimus tablets have roughly 15% absolute bioavailability due to first-pass CYP3A4 metabolism in the gut wall and liver. Compounded formulations vary. This is not a minor pharmacokinetic footnote. A twofold difference in absorption is a twofold difference in drug exposure.
- They list "natural rapamycin supplements" without explaining that these products work through entirely different mechanisms. Berberine activates AMPK, which suppresses mTORC1 indirectly. It does not bind FKBP12. The mechanistic distance is substantial.
Bioavailability and Formulation: Why It Matters More Than People Realize
The FDA-approved oral solution of sirolimus has higher bioavailability than the tablet formulation. In pharmacokinetic studies referenced in the Rapamune prescribing information, the tablet formulation provides approximately 27% lower bioavailability than the oral solution when taken in a fasted state. The clinical implication: a 2 mg tablet does not deliver the same exposure as 2 mg of solution.
Food effect: A high-fat meal increased sirolimus Cmax by approximately 34% and AUC by approximately 35% compared to fasted dosing, based on PK data in the Rapamune label. This is clinically meaningful. Patients on therapeutic sirolimus are counseled to take it consistently with or without food, not because food is irrelevant but because consistency of fat intake is required for consistent blood levels.
Grapefruit: Grapefruit and Seville orange contain furanocoumarins that irreversibly inhibit intestinal CYP3A4. Because sirolimus undergoes extensive pre-systemic CYP3A4 metabolism, grapefruit juice can raise sirolimus blood levels substantially and unpredictably. This is not theoretical. It is a documented interaction in the transplant literature. Avoid grapefruit entirely when taking sirolimus at any dose.
Compounded formulation stability: Compounded sirolimus suspensions and capsules do not have the same stability data as Rapamune. Sirolimus is a large lipophilic macrolide sensitive to heat, light, and moisture. Degradation products are not necessarily inert. A reputable compounding pharmacy performs stability testing; most do not publish it. Always ask for a stability certificate and an expiration date backed by real testing data.
Honest Head-to-Head: Rapamycin vs. Real Alternatives
| Agent | Mechanism | Human Longevity Evidence | Legal Status (US) | Safety Profile | Where Rapamycin Loses |
|---|---|---|---|---|---|
| Sirolimus (compounded) | Direct FKBP12-mTORC1 inhibition | Mechanistic only, 1 phase 2 trial | Prescription required | Mouth sores, lipid changes, wound healing impairment, immunosuppression | Requires Rx, real drug risks, cost, no OTC access |
| Everolimus (rapalog) | Same as sirolimus, shorter half-life | Similar, Mannick 2014 used a related compound | Prescription required | Similar to sirolimus, more predictable PK | More expensive, also Rx-only |
| Berberine | AMPK activation, indirect mTOR suppression | Metabolic benefits (glucose, lipids) in RCTs; no longevity data | OTC supplement | GI side effects, CYP2D6 inhibition | Rapamycin wins on mechanistic directness; berberine wins on safety and legality |
| Spermidine | Autophagy induction (independent of mTOR) | Observational cohort data; small RCTs on cognition | OTC supplement | Generally well tolerated | Rapamycin wins on potency; spermidine wins on safety and OTC access |
| Fisetin | Senolytic, anti-inflammatory, mTOR-adjacent | One small human pilot; mostly animal data | OTC supplement | Very limited human data, probably safe at food doses | Even weaker human evidence than rapamycin; rapamycin has stronger mechanism |
| Metformin | AMPK, mitochondrial complex I inhibition | Large observational data, TAME trial ongoing | Prescription (off-label for longevity) | GI effects, B12 depletion, lactic acidosis risk in renal impairment | More human safety and observational data than rapamycin; rapamycin has more direct mTOR effect |
Bottom line: For a risk-averse individual without physician supervision, berberine or spermidine are the most defensible OTC choices because the risk-benefit calculation at unknown doses from unknown sources favors lower-risk agents. Compounded sirolimus under physician supervision is a legitimate option for appropriately selected adults who understand the risks. The difference in likely effect size between sirolimus and OTC alternatives is unknown in humans. Do not pretend it is established.
How to Read a Compounded Rapamycin Product and Its COA
If you obtain compounded sirolimus legally with a prescription, here is what to verify before taking it:
- Pharmacy registration: Confirm 503A (patient-specific compounding) or 503B (outsourcing facility) status on the FDA database at fda.gov. 503B facilities have stricter cGMP requirements.
- Certificate of Analysis (COA): Should specify the active ingredient as sirolimus (not a generic trade name), quantify it in mg per unit (e.g., 2 mg per capsule), and give a purity percentage from HPLC analysis. Acceptable purity is 95% or higher. Anything lower should prompt questions.
- Third-party testing: The COA should be from an independent, ISO 17025 accredited analytical lab, not just the compounding pharmacy's in-house quality control. Ask specifically whether the testing was third-party.
- Degradation products: Sirolimus degrades to several known impurities. A thorough COA addresses known degradation products, not just total sirolimus content.
- Expiration date with stability support: The expiry must be based on actual stability data for the specific formulation, not just a default date. Ask how the expiry was determined.
- Appearance at dispensing: Sirolimus oral solution is a clear to slightly hazy liquid. Capsules should be uniform in appearance with no clumping or discoloration. Degraded sirolimus solutions may show visible precipitate or color change. Do not use a product that looks different from what was described at dispensing.
Dosing Protocols in the Published Literature
| Protocol Context | Dose | Frequency | Source | Evidence Level |
|---|---|---|---|---|
| Kidney transplant immunosuppression | 2 mg/day (maintenance) after loading | Daily | FDA Rapamune prescribing information | High (approved indication) |
| Immune function in elderly (Mannick 2014) | 0.5 mg/day or 5 mg/week (RAD001) | Daily or weekly for 6 weeks | Mannick et al., Sci Transl Med, 2014 | Moderate (RCT, rapalog, single endpoint) |
| PEARL trial (aging biomarkers) | 1 mg/day | Daily for 8 weeks | Mannick et al., eLife, 2021 | Low to Moderate (phase 2, biomarker only) |
| Typical longevity physician protocol (reported, not RCT-validated) | 2 to 6 mg | Once weekly | Multiple published case series and Kaeberlein lab reports | Very Low (observational, no control) |
Drug and Supplement Interactions You Cannot Ignore
Sirolimus is metabolized by CYP3A4 and is a P-glycoprotein substrate. This creates clinically meaningful interactions:
- CYP3A4 inhibitors (raise sirolimus levels): Grapefruit juice, ketoconazole, itraconazole, clarithromycin, HIV protease inhibitors. Even at low longevity doses, a strong CYP3A4 inhibitor could push blood levels into immunosuppressive or toxic ranges.
- CYP3A4 inducers (lower sirolimus levels): St. John's Wort (Hypericum perforatum) is the most common supplement in this category. It can reduce sirolimus exposure substantially, making an intended dose pharmacologically ineffective. Rifampin and carbamazepine are pharmaceutical examples.
- Calcineurin inhibitors: Cyclosporine dramatically increases sirolimus AUC. Even people who took cyclosporine for a short course previously and have discontinued it may have residual interaction risk during washout.
- ACE inhibitors and ARBs: Combination with sirolimus increases the risk of angioedema. This interaction is noted in the prescribing information and is not widely known outside transplant pharmacology.
- Vaccines: Sirolimus impairs vaccine immunogenicity. If you take a scheduled vaccine (flu, COVID booster, shingles), timing relative to sirolimus dosing matters. Discuss with your physician. This is not a theoretical concern; it was the finding that prompted the Mannick 2014 trial to begin with, because Novartis researchers observed that transplant patients on mTOR inhibitors had poor vaccine responses.
Frequently Asked Questions
Is rapamycin available as an over-the-counter supplement?
No. Rapamycin (sirolimus) is an FDA-approved prescription drug. Products sold as "rapamycin supplements" are either mislabeled, contain analogues, contain plant-derived precursors, or are compounded medications requiring a prescription. No legal OTC supplement contains pharmaceutical-grade sirolimus in meaningful doses.
What is the difference between rapamycin and rapalogs like everolimus?
Rapamycin (sirolimus) is the parent mTOR inhibitor with a half-life of roughly 60 hours in healthy adults. Rapalogs like everolimus are semi-synthetic derivatives with shorter half-lives designed for more predictable dosing. Both inhibit mTORC1 but differ in pharmacokinetics, drug interactions, and cost.
What dose of rapamycin do longevity researchers use?
Most human longevity protocols described in published literature and clinical registries use intermittent low doses, typically 2 mg to 6 mg once weekly, rather than the daily immunosuppressive doses of 1 mg to 5 mg used in transplant medicine. The PEARL trial used 1 mg/day in women over 50.
Does food affect rapamycin absorption?
Yes, significantly. A high-fat meal increased sirolimus peak concentration (Cmax) by roughly 34% and AUC by roughly 35% based on PK data in the Rapamune prescribing information. Consistent fat intake at dosing time matters more than avoiding food entirely. Grapefruit inhibits CYP3A4 and can dramatically raise blood levels unpredictably.
Can berberine or spermidine replace rapamycin?
No. Berberine activates AMPK and has indirect, modest mTOR-suppressing effects. Spermidine induces autophagy through a different pathway. Neither achieves the direct, potent mTORC1 inhibition of sirolimus. They carry a far safer profile and OTC status, making them reasonable low-risk alternatives, not equivalents.
What are the real risks of low-dose intermittent rapamycin?
Known risks even at low doses include mouth sores (aphthous ulcers), transient lipid elevations, delayed wound healing, and potential immunosuppression sufficient to impair vaccine response. The PEARL trial reported some glucose metabolism changes. Long-term safety data from randomized trials in healthy adults is still limited.
How do I verify the quality of a compounded rapamycin product?
Request a Certificate of Analysis from an ISO-accredited third-party lab. Confirm the compounding pharmacy holds 503A or 503B FDA status. Look for HPLC purity data showing sirolimus content at 95% or higher and absence of degradation products. Avoid any vendor that cannot supply these documents on request.
Is rapamycin proven to extend human lifespan?
No. Rapamycin extends lifespan in mice even when started late in life, a finding replicated across multiple NIA Interventions Testing Program sites. Human evidence is mechanistic and observational only. No randomized trial has demonstrated lifespan extension in healthy humans, and this distinction is critical for informed decisions.
What does mTORC1 inhibition actually do at the cellular level?
Sirolimus binds FKBP12, and that complex inhibits mTORC1 by docking near its kinase domain. This reduces phosphorylation of S6K1 and 4E-BP1, slowing ribosome biogenesis and cap-dependent translation. It also promotes autophagy by releasing ULK1 from mTORC1 suppression. mTORC2 is largely spared at standard doses.
Why do compounded rapamycin products vary so much in price?
Price differences reflect compounding overhead, pharmaceutical-grade API sourcing versus lower-grade bulk suppliers, third-party testing costs, and markup. Products priced significantly below market rate often use API of uncertain origin or skip independent purity testing. The raw material cost of sirolimus API is a real floor that prices cannot responsibly fall below.
Should rapamycin be cycled or taken continuously?
Most longevity-focused protocols use once-weekly dosing rather than daily dosing, based on the rationale that intermittent mTORC1 inhibition allows mTORC2-dependent processes to recover between doses. This is a pharmacologically reasonable hypothesis, not a proven protocol. No RCT has compared cycling strategies in healthy adults.
What supplements interact dangerously with rapamycin?
St. John's Wort strongly induces CYP3A4 and P-glycoprotein, potentially reducing sirolimus levels substantially. Grapefruit and Seville orange inhibit CYP3A4 and can raise levels unpredictably. Echinacea, cat's claw, and other immune-modulating herbs add unpredictable immunosuppressive or opposing effects. These interactions are clinically significant even at low doses.
Sources
- Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392-395.
- Mannick JB, Del Giudice G, Lattanzi M, et al. mTOR inhibition improves immune function in the elderly. Science Translational Medicine. 2014;6(268):268ra179.
- Mannick JB, Morris M, Hockey HP, et al. TORC1 inhibition enhances immune function and reduces infections in the elderly. eLife. 2021;10:e67570.
- Pfizer/Wyeth. Rapamune (sirolimus) Prescribing Information. FDA-approved label. Accessed 2026.
- Kaeberlein M. How healthy is the healthspan concept? GeroScience. 2018;40(4):361-364.
- Lamming DW, Ye L, Katajisto P, et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science. 2012;335(6076):1638-1643.
- FDA. 21 CFR Part 111 and Dietary Supplement Health and Education Act (DSHEA) framework. FDA.gov.
- FDA. 503A and 503B Compounding Pharmacy Regulations. FDA.gov. Accessed 2026.
- Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of ULK1. Nature Cell Biology. 2011;13(2):132-141.
- NIA Interventions Testing Program. National Institute on Aging. nia.nih.gov/research/dab/interventions-testing-program-itp. Accessed 2026.
Disclaimers
Platform: FormBlends is an informational resource. Nothing on this page constitutes medical advice, diagnosis,
Related peptide guides
Evidence standard
How this page was source-checked
FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.
PubMed evidence trail
Research sources used to frame this page
For Best Rapamycin Supplement 2026: Evidence-Graded Guide | FormBlends, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not a claim that every study applies to every patient.
Emerging pharmacotherapies for obesity: A systematic review
Broad context for new and established obesity-drug categories.
PubMed
Glucagon-like receptor agonists and next-generation incretin-based medications
Current review for incretin-based obesity medications and cardiometabolic effects.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
Used as a class-level evidence anchor when no more specific citation group matches.
PubMed
Comparison decision path
Use this comparison to narrow the provider review question
Direct answer
Best Rapamycin Supplement 2026: Evidence-Graded Guide should help you decide which option deserves a clinical review, not force a one-size answer.
Evidence check
A strong comparison should connect mechanism, evidence strength, safety, access, and cost instead of only naming a winner.
Safety check
The right choice can change based on history, medication interactions, side effects, budget, and availability.
Next step
After comparing, use the get-started flow to route your goals and health history into the right prescription review path.
Original tools and data
Use the FormBlends research stack
These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.
Editorial refresh
Practical 2026 note for Best Rapamycin Supplement 2026
For this peptide therapy page, the 2026 refresh focuses on cash-pay pricing, safety signals, best, rapamycin, supplement so the article stays close to the question behind "Best Rapamycin Supplement 2026".
The useful details are the practical ones: what to verify, what changes risk or cost, and which details separate Best Rapamycin Supplement 2026 from nearby GLP-1, peptide, hormone, or provider-comparison searches.
Readers can use the added context to bring sharper questions to a licensed provider before making a treatment, cost, or care decision.
Custom 2026 image for Best Rapamycin Supplement 2026, peptide therapy, and better treatment decision-making.
Download the Peptide Quick Reference Card
A printable 2-page reference covering popular peptides, dosing ranges, stacking protocols, and storage.
Free download. We'll also send helpful GLP-1 guides to your inbox. Unsubscribe anytime.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.
Written by FormBlends Medical Content Team
Medical content team. This article was researched against primary regulatory, trial, prescribing, and manufacturer sources where available. Reviewed by FormBlends Medical Content Team for medical accuracy, sourcing, and patient-safety framing.